D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $2.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 288.35% from the company’s current price.

Separately, HC Wainwright boosted their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th.

Lineage Cell Therapeutics Stock Up 2.5 %

Shares of NYSEAMERICAN:LCTX opened at $0.52 on Friday. Lineage Cell Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.61. The firm has a market capitalization of $113.52 million, a price-to-earnings ratio of -4.29 and a beta of 1.16.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LCTX. State Street Corp raised its holdings in Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after acquiring an additional 45,483 shares during the last quarter. Raffles Associates LP boosted its stake in shares of Lineage Cell Therapeutics by 35.8% during the second quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock worth $4,346,000 after buying an additional 1,147,800 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Lineage Cell Therapeutics by 35.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after buying an additional 114,762 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after acquiring an additional 17,411 shares during the period. Finally, XTX Topco Ltd purchased a new position in Lineage Cell Therapeutics during the 2nd quarter valued at about $61,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.